You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧泰生物(688606.SH):計劃新建年產4億人份體外診斷試劑生產研發中心建設項目
格隆匯 05-08 20:49

格隆匯5月8日丨奧泰生物(688606.SH)公佈,近年來,隨着醫學診斷和治療水平的不斷提高,體外快速診斷試劑憑藉其使用便捷、應用範圍廣泛的特點,不斷受到人們的關注和重視,目前已成為體外診斷行業發展最快的細分領域之一。特別是新冠病毒的防疫檢測,更是凸顯了體外快速診斷試劑的發展可期。為滿足國際市場客户對體外快速診斷檢測試劑產品數量、質量和品種的需求,公司將在膠體金平台、生化試劑平台、熒光試劑平台的基礎上,擴大延伸至化學發光檢測平台、PCR檢測平台、電子儀器檢測平台,增加實驗室檢驗流水線、數字PCR、微流控凝血等項目。公司將計劃新建年產4億人份體外診斷試劑生產研發中心建設項目,從而豐富產品種類,提高生產能力,4擴大業務規模。

該項目由全資子公司杭州奧愷生物技術有限公司(“奧愷生物”)實施,預計總投資金額6.4億元人民幣(最終項目投資總額以實際投資為準)。公司擬使用部分超募資金投入該項目。

項目建設期3,建設完成後第3年達產,達產後預計新增年收入6億元,淨利潤2億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account